emat

Buy Complete Report

Prix: €120 HT

Logo CreditCards Visa Logo CreditCards Mastercard

This report is accessible on EMAT, the reference database for private company acquisition multiples

 

 

► Subscribe to EMAT database

 

Sectors covered by our analysts

 

► Studies & indices published by Epsilon Research: Register to receive (free) publications updates

 

► Alert on reports published: Sign up (free) to receive by e-mail updates on EMAT reports published on your preferred sector.

 

Transaction Multiples for the Valuation of Private Companies

Private group led by Exponent Private Equity / Chanelle Pharma

No EMAT : 116340
Announced Date : 07/02/2024
Type : LBO (Leverage Buy Out)
Deal Value : Yes
Acquirer : Private group led by Exponent Private Equity

Target : Chanelle Pharma
Country : Ireland
Sector of activity :
  • Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Pharmaceuticals
  • Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Veterinary Pharmaceuticals
Business Description :
Founded in 1985 by Michael H Burke, Chanelle Pharma is the Ireland’s largest manufacturer of generic pharmaceuticals for animal and human health. > With a presence in over 80 countries, Chanelle...

Transaction multiples available
EV/
Sales
EV/
Gross Profit
EV/
EBITDA
EV/
EBIT
Eq/
PBT
P/E Price
to Book
Specific
multiple(s)
Historic
Current
Rating : **
Multiple available
n.s.   Multiple calculated, but not significant

Source: Epsilon Research / EMAT

Comparable Transactions

  • Number of EMAT Reports / sub-sector « Pharmaceuticals » = 129
  • Number of EMAT Reports / sub-sector « Veterinary Pharmaceuticals » = 34
Example of comparable transactions on EMAT (same sub-sector):
Date Acquirer Target Country Multiples See details
23/08/2021 Vimian Group Check-Points Netherlands ** 116329
03/07/2023 Novacyt Yourgene Health United Kingdom ** 116303

Source: Epsilon Research / EMAT

About Epsilon Research

Epsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.

EMAT Report

► Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).

 

► Example of EMAT Report